• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于阿片类药物成瘾的药物辅助治疗(MAT):特刊介绍

Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue.

作者信息

McElrath Karen, Joseph Herman

机构信息

a Department of Criminal Justice , Fayetteville State University , Fayetteville , North Carolina , USA.

b National Development and Research Institutes , New York City, New York , USA.

出版信息

Subst Use Misuse. 2018 Jan 28;53(2):177-180. doi: 10.1080/10826084.2017.1404106. Epub 2017 Dec 8.

DOI:10.1080/10826084.2017.1404106
PMID:29220615
Abstract

Several countries are experiencing public health crises as a result of opioid addiction. Fatal overdoses have reached record highs in many regions and Hepatitis C virus is the norm among people who inject drugs in several countries. Thus, providing for the global availability of medication-assisted treatment (MAT) for opioid addiction is more important than ever. In this article, we introduce readers to the collection of papers that appear in this special issue on MAT for opioid addiction. We describe the articles and commentaries thematically to include topics that address 1) the contemporary history of methadone maintenance, 2) the provision of and access and barriers to MAT, 3) compliance and outcomes of MAT, 4) health issues among MAT patients, 5) race, ethnicity, and social class backgrounds of MAT patients, 6) criminalization and stigma, and 7) challenges associated with the expansion of MAT.

摘要

由于阿片类药物成瘾,一些国家正面临公共卫生危机。在许多地区,致命过量用药已达到创纪录的高水平,并且丙型肝炎病毒在一些国家注射毒品的人群中很常见。因此,确保全球范围内可获得用于治疗阿片类药物成瘾的药物辅助治疗(MAT)比以往任何时候都更加重要。在本文中,我们向读者介绍本期关于阿片类药物成瘾的药物辅助治疗的特刊中所收录的论文。我们按主题对这些文章和评论进行了描述,包括涉及以下方面的主题:1)美沙酮维持治疗的当代历史,2)药物辅助治疗的提供、获取及障碍,3)药物辅助治疗的依从性和效果,4)药物辅助治疗患者的健康问题,5)药物辅助治疗患者的种族、族裔和社会阶层背景,6)刑事定罪和污名化,以及7)与药物辅助治疗扩展相关的挑战。

相似文献

1
Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue.用于阿片类药物成瘾的药物辅助治疗(MAT):特刊介绍
Subst Use Misuse. 2018 Jan 28;53(2):177-180. doi: 10.1080/10826084.2017.1404106. Epub 2017 Dec 8.
2
Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary.美国阿片类药物成瘾的药物辅助治疗:批判与评论
Subst Use Misuse. 2018 Jan 28;53(2):334-343. doi: 10.1080/10826084.2017.1342662. Epub 2017 Sep 1.
3
Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access.新墨西哥州监禁的阿片类药物依赖者的药物辅助治疗:全州范围内努力增加获取途径。
Subst Abus. 2012;33(1):76-84. doi: 10.1080/08897077.2011.611455.
4
Intervention stigma: How medication-assisted treatment marginalizes patients and providers.干预污名:药物辅助治疗如何使患者和提供者边缘化。
Soc Sci Med. 2019 Jul;232:324-331. doi: 10.1016/j.socscimed.2019.05.027. Epub 2019 May 17.
5
Pharmacotherapy of Opioid Addiction: "Putting a Real Face on a False Demon".阿片类药物成瘾的药物治疗:“让虚假恶魔现出真面目”
J Med Toxicol. 2016 Mar;12(1):58-63. doi: 10.1007/s13181-015-0517-5.
6
Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.美沙酮、丁丙诺啡与阿片类激动剂治疗偏好:一项定性分析。
Drug Alcohol Depend. 2016 Mar 1;160:112-8. doi: 10.1016/j.drugalcdep.2015.12.031. Epub 2016 Jan 6.
7
Use and misuse of opioid agonists in opioid addiction.阿片类药物成瘾中阿片类激动剂的使用和滥用。
Cleve Clin J Med. 2017 May;84(5):377-384. doi: 10.3949/ccjm.84a.16091.
8
Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year.双重精神健康诊断预测药物辅助阿片类药物治疗的接受情况:与州医疗补助扩张状况、种族/民族和性别以及年份有关的关联。
Drug Alcohol Depend. 2020 Apr 1;209:107952. doi: 10.1016/j.drugalcdep.2020.107952. Epub 2020 Mar 7.
9
The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.将药物辅助治疗阿片类药物成瘾与移动健康相结合的效果:一项随机临床试验的研究方案
Trials. 2016 Dec 12;17(1):592. doi: 10.1186/s13063-016-1726-1.
10
Opioid substitution treatment in New Zealand: a 40 year perspective.新西兰的阿片类药物替代治疗:40年回顾
N Z Med J. 2014 Jul 4;127(1397):57-66.

引用本文的文献

1
Fentanyl and xylazine crisis: Crafting coherent strategies for opioid overdose prevention.芬太尼和赛拉嗪危机:制定连贯的阿片类药物过量预防策略。
World J Psychiatry. 2024 Jun 19;14(6):760-766. doi: 10.5498/wjp.v14.i6.760.
2
Latent class analysis of perceived stigma among older adults receiving medications for opioid use disorder.老年阿片类药物使用障碍药物治疗者感知污名的潜在类别分析。
J Subst Use Addict Treat. 2024 Jan;156:209187. doi: 10.1016/j.josat.2023.209187. Epub 2023 Oct 18.
3
An observational study on the use of long acting buprenorphine (ublocade) and a amper resistant PICC for utpatient IV antibiotic administration in atients with serious infections and pioid se isorder; The project.
一项关于长效丁丙诺啡(ublocade)和耐安培外周静脉中心静脉导管在患有严重感染和阿片类物质使用障碍患者门诊静脉注射抗生素治疗中的应用的观察性研究;该项目。
Drug Alcohol Depend Rep. 2021 Dec 20;2:100020. doi: 10.1016/j.dadr.2021.100020. eCollection 2022 Mar.
4
Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review.阿片类药物成瘾的历史路径、传统及替代治疗方案(包括氯胺酮、大麻素和去甲诺勃卡因)的戒断:一项叙述性综述
Health Psychol Res. 2022 Oct 7;10(4):38672. doi: 10.52965/001c.38672. eCollection 2022.
5
Combination Therapy and Opioids: Effectiveness of Transcranial Direct-Current Stimulation (tDCS) and Emotion Regulation Training in Reducing Current Drug Craving.联合治疗与阿片类药物:经颅直流电刺激(tDCS)和情绪调节训练在减轻当前药物渴望方面的有效性。
Maedica (Bucur). 2020 Mar;15(1):53-60. doi: 10.26574/maedica.2020.15.1.53.
6
Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year.双重精神健康诊断预测药物辅助阿片类药物治疗的接受情况:与州医疗补助扩张状况、种族/民族和性别以及年份有关的关联。
Drug Alcohol Depend. 2020 Apr 1;209:107952. doi: 10.1016/j.drugalcdep.2020.107952. Epub 2020 Mar 7.